Literature DB >> 32139507

The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Yue Zhao1,2, Tian-Yu Wu1, Meng-Fei Zhao1, Chao-Jun Li3,2.   

Abstract

Protein prenylation is an essential posttranslational modification and includes protein farnesylation and geranylgeranylation using farnesyl diphosphate or geranylgeranyl diphosphate as substrates, respectively. Geranylgeranyl diphosphate synthase is a branch point enzyme in the mevalonate pathway that affects the ratio of farnesyl diphosphate to geranylgeranyl diphosphate. Abnormal geranylgeranyl diphosphate synthase expression and activity can therefore disrupt the balance of farnesylation and geranylgeranylation and alter the ratio between farnesylated and geranylgeranylated proteins. This change is associated with the progression of nonalcoholic fatty liver disease (NAFLD), a condition characterized by hepatic fat overload. Of note, differential accumulation of farnesylated and geranylgeranylated proteins has been associated with differential stages of NAFLD and NAFLD-associated liver fibrosis. In this review, we summarize key aspects of protein prenylation as well as advances that have uncovered the regulation of associated metabolic patterns and signaling pathways, such as Ras GTPase signaling, involved in NAFLD progression. Additionally, we discuss unique opportunities for targeting prenylation in NAFLD/hepatocellular carcinoma with agents such as statins and bisphosphonates to improve clinical outcomes.
© 2020 Zhao et al.

Entities:  

Keywords:  cell signaling; geranylgeranyl diphosphate synthase (GGPPS); glucose metabolism; hepatocellular carcinoma (HCC); lipid metabolism; lipid modification; liver fibrosis; liver metabolism; metabolic disorder; metabolic pattern; nonalcoholic fatty liver disease; posttranslational modification; prenylation; protein isoprenylation; signaling pathway

Mesh:

Substances:

Year:  2020        PMID: 32139507      PMCID: PMC7152775          DOI: 10.1074/jbc.REV119.008897

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  118 in total

Review 1.  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos S Mantzoros
Journal:  Metabolism       Date:  2018-11-29       Impact factor: 8.694

2.  Structure of the yeast oligosaccharyltransferase complex gives insight into eukaryotic N-glycosylation.

Authors:  Rebekka Wild; Julia Kowal; Jillianne Eyring; Elsy M Ngwa; Markus Aebi; Kaspar P Locher
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

Review 3.  Statin-associated myopathy.

Authors:  Paul D Thompson; Priscilla Clarkson; Richard H Karas
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

4.  PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP.

Authors:  Thomas Porstmann; Beatrice Griffiths; Yuen-Li Chung; Oona Delpuech; John R Griffiths; Julian Downward; Almut Schulze
Journal:  Oncogene       Date:  2005-09-29       Impact factor: 9.867

Review 5.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

Review 6.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

7.  Vascular endothelial growth factor activation of sterol regulatory element binding protein: a potential role in angiogenesis.

Authors:  Rui-Hai Zhou; Min Yao; Tzong-Shyuan Lee; Yi Zhu; Manuela Martins-Green; John Y-J Shyy
Journal:  Circ Res       Date:  2004-07-22       Impact factor: 17.367

Review 8.  Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities.

Authors:  Robert S Rosenson
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

9.  Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.

Authors:  D Amin; S A Cornell; S K Gustafson; S J Needle; J W Ullrich; G E Bilder; M H Perrone
Journal:  J Lipid Res       Date:  1992-11       Impact factor: 5.922

10.  A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

Authors:  Jean-Luc Harousseau; Giovanni Martinelli; Wieslaw W Jedrzejczak; Joseph M Brandwein; Dominique Bordessoule; Tamas Masszi; Gert J Ossenkoppele; Julia A Alexeeva; Gernot Beutel; Johan Maertens; Maria-Belen Vidriales; Hervé Dombret; Xavier Thomas; Alan K Burnett; Tadeusz Robak; Nuriet K Khuageva; Anatoly K Golenkov; Elena Tothova; Lars Mollgard; Youn C Park; Annick Bessems; Peter De Porre; Angela J Howes
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

View more
  6 in total

1.  Bioinformatics analysis of an animal model of diet-induced nonalcoholic fatty liver disease with rapid progression.

Authors:  Wei Hong; Tingting Zhang; Junbin Yan; Jianshun Yu; Beihui He; Liyan Wu; Kannan Yao; Wei Mao; Zhiyun Chen
Journal:  Exp Biol Med (Maywood)       Date:  2021-11-13

2.  Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs.

Authors:  Álvaro Del Real; Carmen Valero; José M Olmos; Jose L Hernández; José A Riancho
Journal:  Pharmaceutics       Date:  2022-04-02       Impact factor: 6.525

3.  Type 1 polyisoprenoid diphosphate phosphatase modulates geranylgeranyl-mediated control of HMG CoA reductase and UBIAD1.

Authors:  Rania Elsabrouty; Youngah Jo; Seonghwan Hwang; Dong-Jae Jun; Russell A DeBose-Boyd
Journal:  Elife       Date:  2021-11-29       Impact factor: 8.140

4.  Inhibition of Orbivirus Replication by Fluvastatin and Identification of the Key Elements of the Mevalonate Pathway Involved.

Authors:  Fauziah Mohd Jaafar; Baptiste Monsion; Mourad Belhouchet; Peter P C Mertens; Houssam Attoui
Journal:  Viruses       Date:  2021-07-23       Impact factor: 5.048

5.  Transcriptome changes in stages of non-alcoholic fatty liver disease.

Authors:  Jihad Aljabban; Michael Rohr; Saad Syed; Kamal Khorfan; Vincent Borkowski; Hisham Aljabban; Michael Segal; Mohamed Mukhtar; Mohammed Mohammed; Maryam Panahiazar; Dexter Hadley; Ryan Spengler; Erin Spengler
Journal:  World J Hepatol       Date:  2022-07-27

Review 6.  Prenylation Defects and Oxidative Stress Trigger the Main Consequences of Neuroinflammation Linked to Mevalonate Pathway Deregulation.

Authors:  Simona Pisanti; Erika Rimondi; Elena Pozza; Elisabetta Melloni; Enrico Zauli; Maurizio Bifulco; Rosanna Martinelli; Annalisa Marcuzzi
Journal:  Int J Environ Res Public Health       Date:  2022-07-25       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.